Abstract
Recent guidelines recommend initiation of antihypertensive therapy with fixed-dose combinations in high-risk patients because such patients usually need two or more blood pressure (BP)-lowering agents in order to normalize their BP. Agents that block the renin-angiotensin system (ACE inhibitors or angiotensin II receptor antagonists [angiotensin receptor blockers; ARBs]) are preferred for the management of hypertension in most patients exhibiting subclinical target organ damage, or established cardiovascular or renal diseases. Unless contraindicated they should be one of the components of fixed-dose combinations, whereas the other component may be either a calcium channel antagonist or a thiazide diuretic. Fixed-dose combinations containing an ACE inhibitor or ARB plus a calcium channel antagonist appear particularly effective in preventing complications of coronary heart disease.
Similar content being viewed by others
References
Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–60
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–23
Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–76
Williams B. Recent hypertension trials: implications and controversies. J Am Coll Cardiol 2005; 45: 813–27
Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–9
Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121–3
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52
Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87
Brunner HR, Menard J, Waeber B, et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990; 8: 3–11
Zanchetti A. Angiotensin converting enzyme inhibition in clinical practice: a re-examination of stepped-care: a retrospective and a prospective. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: S126–31
Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the ‘rule of halves’ still valid? J Hum Hypertens 1997; 11: 213–20
Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–7
Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167: 141–7
Mancia G, Pessina AC, Trimarco B, et al. Blood pressure control according to new guidelines targets in low- to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22: 2387–96
Banegas JR, Segura J, Ruilope LM, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43: 1338–44
Amar J, Vaur L, Perret M, et al. Hypertension in high-risk patients: beware of the under use of effective combination therapy (results of the PRATIK study). J Hypertens 2002; 20: 779–84
Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001; 61: 943–54
White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit 2008; 13: 123–9
Struijker-Boudier HA, Ambrosioni E, Holzgreve H, et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int J Clin Pract 2007; 61: 1592–602
Rosenthal T, Gavras I. Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis 2006; 48: 416–25
Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Press 2001; 10: 62–73
Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713–9
Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591–603
Dickerson CJE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008–13
Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427–31
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31
Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59
Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–16
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2977–81
Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003
Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2000; 4: 393–404
Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50: 299–305
Fagard RH, Van den Enden M, Leeman M, et al. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297–302
Van der Niepen P, Giot C, van de Borne P. Prevalence of isolated uncontrolled systolic blood pressure among treated hypertensive patients in primary care in Belgium: results of the I-inSYST survey. J Hypertens 2008; 26: 2057–63
Roux O, Chapellier M, Czernichow S, et al. Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Press 2006; 15: 6–13
Steckelings UM, Stoppelhaar M, Sharma AM, et al. HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Press 2004; 13: 80–8
Mancia G, Ambrosioni E, Rosei EA, et al. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005; 23: 1575–81
Kjeldsen SE, Naditch-Brule L, Perlini S, et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the global cardiometabolic risk profile in patients with hypertension disease survey. J Hypertens 2008; 26: 2064–70
European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53
Moser M. Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument for. J Clin Hypertens 2005; 7: 111–6
Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotens Aldoster Sys 2006; 7: 61–3
Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203–9
Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J 1983; 106: 245–51
Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72
Berglund G, Andersson O. Hydrochlorothiazide and spironolactone alone and in a fixed combination in hypertension. Curr Ther Res 1980; 27: 360–4
Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131–41
Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53
Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9
Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10
Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25
Pedersen ME, Cockcroft JR. The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep 2006; 8: 279–86
Naylor WG. The potential for added benefits with beta-blockers and calcium antagonists in treating cardiovascular disorders. Drugs 1988; 35 Suppl. 4: 1–8
Waeber B. Position of fixed-dose combinations containing an AT(1)-receptor blocker and a thiazide diuretic. Blood Press 2005; 14: 324–36
Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003; 1: 43–50
Brunner HR, Waeber B, Nussberger J. Renin secretion responsiveness: understanding the efficacy of reninangiotensin inhibition. Kidney Int 1988; 26: S80–S5
Hall D, Motoro R, Littlejohn T, et al. Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension. Clin Drug Invest 1998; 16: 203–10
MacKay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278–85
Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797–805
Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7: S52–S5
Malini PL, Strocchi E, Ambrosioni E, et al. Long-term antihypertensive, metabolic and cellular effects of enalapril. J Hypertens 1984; 2: S101–S5
Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20: 369–79
Johnson RJ, Kivlighn SD, Kim YG, et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33: 225–34
Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–9
Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861–6
McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833–50
Laurent S. Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension. J Hypertens 2001; 19 Suppl. 4: S9–14
Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063–71
Dahlöf B, Gosse P, Guéret P, et al. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 23: 2063–70
Patel A, MacMahon S, Chalmers J, et al. Effects of fixed combination of perindopril and indapamide on microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–40
Franklin S, Lapuerta P, Cox D, et al. Initial combination therapy with irbesartan/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy. J Clin Hypertens 2007; 9 Suppl. 5: 15–22
Black HR, Levy DG, Crikelair N, et al. Predictive age- and dose-related responses to antihypertensive therapy: pooled analysis of two randomized clinical trials of valsartan alone and combined with hydrochlorothiazide. J Am Soc Hypertens 2008; 2: 476–83
Waeber B, Mourad JJ. Targeting systolic blood pressure: the key to controlling combined systolic/diastolic hypertension. Am J Hypertens 2006; 19: 985–6
Gojanovic B, Feihl F, Liaudet L, et al. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotens Aldoster Sys 2008; 9: 1–9
Gradman AH, Weir MR, Bakris GL. Newer combination therapies in the management of hypertension: an update. J Clin Hypertens 2008; 10: 398–405
Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–28
Grossman E, Messerli FH. Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis 2006; 49: 16–25
Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. Drugs 1998; 55: 509–17
Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. Am J Cardiol 1997; 80: 1453–8
Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003; 63: 2449–72
Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20mg, and placebo. Clin Ther 1996; 18: 1213–24
Karlberg BE, Andrup M, Oden A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Blood Press 2000; 9: 140–5
Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensinconverting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000; 86: 1182–7
Pool J, Kaihlanen P, Lewis G, et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001; 15: 495–8
Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17: 495–501
Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563–80
Luft FC, Aronoff GR, Sloan RS, et al. Calcium channel blockade with nitrendipine: effects on sodium home-ostasis, the renin-angiotensin system, and the sympathetic nervous system in humans. Hypertension 1985; 7: 438–42
Gennari C, Nami R, Pavese G, et al. Calcium-channel blockade (nitrendipine) in combination with ACE inhibition (captopril) in the treatment of mild to moderate hypertension. Cardiovasc Drug Ther 1989; 3 Suppl. 1: 319–25
Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Reports 2002; 4: 479–82
Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14: 963–8
Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007; 21: 220–4
Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592–7
Cooper-Dehoff R, Cohen JD, Bakris GL, et al. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006; 98: 890–4
Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341: 1447–57
Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis 2004; 47: 34–57
Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007; 29: 279–89
Rudd P. Clinicians and patients with hypertension: unsettled issues about compliance. Am Heart J 1995; 130: 572–89
Waeber B, Brunner HR, Metry JM. Compliance with antihypertensive treatment: implications for practice. Blood Press 1997; 6: 326–31
Maronde RF, Chan LS, Larsen FJ, et al. Underutilization of antihypertensive drugs and associated hospitalization. Med Care 1989; 27: 1159–66
McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214–26
Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997; 10: 697–704
Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 Suppl.: 2–6
Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail 2003; 9: 324–32
Giles TD, Berk BC, Black HR, et al. Expanding the definition and classification of hypertension. J Clin Hypertens 2005; 7: 505–12
Basile J, Houston M, Ferrario C. Incremental risk-factor reduction improves overall cardiovascular benefit: is it time to abandon the silos? J Clin Hypertens 2006; 8: 686–8
Acknowledgements
No sources of funding were used to assist in the preparation of this review and the authors declare that they are alone responsible for the content. Dr Waeber has received honoraria from Novartis, Servier, Abbott, Sanofi-aventis, AstraZeneca, Daiichi Sankyo and Menarini. Dr Ruilope received honoraria from Novartis, Bayer, Sanofi-aventis, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Servier, Menarini, AstraZeneca, Takeda and Daiichi-Sankyo, and research grants from Novartis, Bayer, Sanofi-aventis and Daiichi-Sankyo. Dr Feihl has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Waeber, B., Feihl, F. & Ruilope, L.M. Fixed-Dose Combinations as Initial Therapy for Hypertension. Drugs 69, 1761–1776 (2009). https://doi.org/10.2165/11316710-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11316710-000000000-00000